Skip to main content
SpringerLink
Log in

Characterization of HER2 Status by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC)

  • Protocol
  • First Online:
Histopathology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1180))

Abstract

The use of human epidermal growth factor receptor type 2 (HER2) gene amplification and overexpression as a molecular predictive marker has become critically important for proper selection of breast cancer patients for treatment with targeted therapeutic agents such as trastuzumab, lapatinib, pertuzumab, and T-DM1. A high level of sensitivity and specificity of molecular tests for this alteration is desirable. The American Society of Clinical Oncology and College of American Pathology have jointly established consensus guidelines to standardize characterization of this alteration in breast cancers. This chapter provides a brief overview of pre-analytic and analytical processing of breast specimens as well as subsequent molecular evaluation for HER2 status.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  2. Press MF, Bernstein L, Thomas PA et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894–2904

    CAS  PubMed  Google Scholar 

  3. Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4014

    Article  PubMed  Google Scholar 

  5. Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138:241–256 [epub ahead of print PMID: 24099077]

    Article  PubMed Central  PubMed  Google Scholar 

  6. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145

    Article  CAS  PubMed  Google Scholar 

  7. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43

    CAS  PubMed  Google Scholar 

  8. Khoury T, Sait S, Hwang H et al (2009) Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457–1467

    Article  CAS  PubMed  Google Scholar 

  9. Engel KB, Moore HM (2011) Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 135:537–543

    PubMed  Google Scholar 

  10. Ibarra JA, Rogers LW (2010) Fixation time does not affect expression of HER2/neu: a pilot study. Am J Clin Pathol 134:594–596

    Article  PubMed  Google Scholar 

  11. Mirlacher M, Kasper M, Storz M et al (2004) Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17:1414–1420

    Article  PubMed  Google Scholar 

  12. Press MF, Finn RS, Cameron D et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861–7870

    Article  CAS  PubMed  Google Scholar 

  13. Press MF, Sauter G, Buyse M et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859–867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333

    Article  CAS  PubMed  Google Scholar 

  15. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607

    Article  CAS  PubMed  Google Scholar 

  16. Press MF, Slamon DJ, Flom KJ et al (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095–3105

    CAS  PubMed  Google Scholar 

  17. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953–962

    CAS  PubMed  Google Scholar 

  18. Press MF, Hung G, Godolphin W et al (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771–2777

    CAS  PubMed  Google Scholar 

  19. Press MF, Pike MC, Chazin VR et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970

    CAS  PubMed  Google Scholar 

  20. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  CAS  PubMed  Google Scholar 

  21. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795

    Article  PubMed Central  PubMed  Google Scholar 

  22. Di Leo A, Gomez HL, Aziz Z et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544–5552

    Article  PubMed Central  PubMed  Google Scholar 

  23. Mass RD, Press MF, Anderson S et al (2005) Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240–246

    Article  PubMed  Google Scholar 

  24. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  CAS  PubMed  Google Scholar 

  25. Perez EA, Dueck AC, McCullough AE et al (2012) Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:159–162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  CAS  PubMed  Google Scholar 

  27. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  CAS  PubMed  Google Scholar 

  28. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  29. Dowsett M, Procter M, McCaskill-Stevens W et al (2009) Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol 27:2962–2969

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Williams JH, Mepham BL, Wright DH (1997) Tissue preparation for immunocytochemistry. J Clin Pathol 50:422–428

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. von Wasielewski R, Mengel M, Wiese B et al (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675–682

    Article  Google Scholar 

  32. Atkins D, Reiffen KA, Tegtmeier CL et al (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52:893–901

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA

    Oliver A. Press, Roberta Guzman, Monica Cervantes & Angela Santiago

  2. Department of Pathology, Norris Comprehensive Cancer Center, NOR5409, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA

    Michael F. Press M.D., Ph.D.

Authors
  1. Oliver A. Press
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta Guzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monica Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Santiago
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael F. Press M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael F. Press M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology, USC Keck School of Medicine, Los Angeles, California, USA

    Christina E. Day

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Press, O.A., Guzman, R., Cervantes, M., Santiago, A., Press, M.F. (2014). Characterization of HER2 Status by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC). In: Day, C. (eds) Histopathology. Methods in Molecular Biology, vol 1180. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1050-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1050-2_10

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1049-6

  • Online ISBN: 978-1-4939-1050-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation